Y-mAbs Therapeutics, Inc. (YMAB)
Sep 15, 2025 - YMAB was delisted (reason: acquired by SERB Pharmaceuticals)
8.61
+0.02 (0.23%)
Inactive · Last trade price on Sep 15, 2025
Y-mAbs Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 85.39 | 87.69 | 84.82 | 65.27 | 34.9 | 20.75 | |
Revenue Growth | -1.34% | 3.38% | 29.96% | 87.03% | 68.18% | - |
Cost of Revenue | 15.8 | 15.25 | 11.42 | 7.57 | 2.51 | 2.2 |
Gross Profit | 69.58 | 72.43 | 73.4 | 57.7 | 32.38 | 18.55 |
Selling, General & Admin | 44.76 | 50.13 | 44.5 | 52.47 | 56.94 | 45.9 |
Research & Development | 42.94 | 47.41 | 50.09 | 88.55 | 90.88 | 92.58 |
Operating Expenses | 87.7 | 97.54 | 94.59 | 141.02 | 147.82 | 138.48 |
Operating Income | -18.11 | -25.11 | -21.19 | -83.32 | -115.43 | -119.94 |
Interest Expense | - | - | - | - | -1.85 | - |
Interest & Investment Income | 6.07 | 3.43 | 4.28 | 0.64 | - | 0.02 |
Currency Exchange Gain (Loss) | -2.04 | -2.04 | 0.52 | - | - | 0.58 |
EBT Excluding Unusual Items | -14.08 | -23.72 | -16.38 | -82.68 | -117.29 | -119.34 |
Merger & Restructuring Charges | -3.97 | -1.52 | -4.48 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | 62.01 | - |
Asset Writedown | - | - | - | -0.62 | - | - |
Legal Settlements | -3.85 | -3.85 | - | - | - | - |
Other Unusual Items | -0.72 | -0.72 | - | -12.28 | - | - |
Pretax Income | -22.62 | -29.81 | -20.87 | -95.57 | -55.28 | -119.34 |
Income Tax Expense | -0.39 | -0.15 | 0.56 | - | - | - |
Net Income | -22.22 | -29.67 | -21.43 | -95.57 | -55.28 | -119.34 |
Net Income to Common | -22.22 | -29.67 | -21.43 | -95.57 | -55.28 | -119.34 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 45 | 44 | 44 | 44 | 43 | 40 |
Shares Outstanding (Diluted) | 45 | 44 | 44 | 44 | 43 | 40 |
Shares Change | 2.79% | 1.57% | -0.13% | 1.21% | 7.64% | 14.03% |
EPS (Basic) | -0.49 | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 |
EPS (Diluted) | -0.49 | -0.67 | -0.49 | -2.19 | -1.28 | -2.97 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Free Cash Flow | -17.92 | -15.71 | -27.23 | -75.92 | -103.22 | -91.41 |
Free Cash Flow Per Share | -0.40 | -0.35 | -0.62 | -1.74 | -2.39 | -2.28 |
Gross Margin | 81.49% | 82.61% | 86.54% | 88.41% | 92.80% | 89.38% |
Operating Margin | -21.21% | -28.64% | -24.98% | -127.66% | -330.78% | -578.00% |
Profit Margin | -26.03% | -33.83% | -25.26% | -146.43% | -158.40% | -575.12% |
Free Cash Flow Margin | -20.99% | -17.92% | -32.11% | -116.32% | -295.79% | -440.51% |
EBITDA | -17.77 | -24.58 | -20.46 | -82.48 | -114.65 | -119.54 |
EBITDA Margin | -20.81% | -28.03% | -24.12% | -126.37% | - | - |
D&A For EBITDA | 0.35 | 0.54 | 0.74 | 0.84 | 0.78 | 0.4 |
EBIT | -18.11 | -25.11 | -21.19 | -83.32 | -115.43 | -119.94 |
EBIT Margin | -21.21% | -28.64% | -24.98% | -127.66% | - | - |
Revenue as Reported | 85.39 | 87.69 | 84.82 | 65.27 | 34.9 | 20.75 |